Orchiectomy has fewer adverse effects than chemical castration for metastatic prostate cancer

Medical castration is associated with a higher risk of adverse effects than surgical castration in men with metastatic prostate cancer, research published in JAMA Oncology has found.1

Androgen deprivation therapy is a mainstay in the treatment of prostate cancer and can be achieved either surgically or pharmacologically with gonadotrophin releasing hormone analogues (GnRHa). In recent years medical castration has largely replaced …